This study is testing a combination of three drugs—belantamab mafodotin, pomalidomide, and dexamethasone—on patients with high-risk myeloma, a type of blood cancer. Belantamab mafodotin is a special drug that targets cancer cells and delivers another drug called mafodotin to destroy them. Pomalidomide stops cancer cells from growing and spreading. Dexamethasone reduces inflammation and is often used with other cancer drugs.
Participants will receive these drugs in 28-day cycles, with some drugs given by IV (intravenous or directly into a vein) and others taken by mouth. This will continue unless there are side effects or the disease gets worse. After treatment, patients will have check-ups every three months.
- Study involves regular cycles of treatment and follow-up visits.
- Participants must meet specific health criteria to join.
- Certain conditions and previous treatments may exclude participants.
How understandable was the trial content above?
Hard to understand
Easy to understand